专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

US20100048601A1 HYDROCHLORIDE SALTS OF 8-[-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one AND PREPARATION PROCESS THEREFOR 有权
标题翻译： 8 - [ - 甲基] -8-苯基-1,7-二氮杂 - 螺[4.5]癸-2-酮的盐酸盐及其制备方法
公开(公告)号：US20100048601A1
公开(公告)日：2010-02-25
申请号：US12614108
申请日：2009-11-06
申请人： Mengwei Hu , Sunil Paliwal , Neng-Yang Shih , Frank Bruno Guenter , Ingrid Mergelsberg
发明人： Mengwei Hu , Sunil Paliwal , Neng-Yang Shih , Frank Bruno Guenter , Ingrid Mergelsberg
IPC分类号： A61K31/438 , C07D471/10 , A61P1/08
CPC分类号： C07D471/10 , A61K31/435 , A61K31/495 , A61K45/06 , C07B2200/13
摘要： Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8-S[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.
摘要翻译：公开了（5S，8S）-8-S [（（1R）-1-（3,5-双 - （三氟甲基）苯基） - 乙氧基} - 甲基] -8-苯基-1 ，7-二氮杂螺[4.5]癸-2-酮，及其制备方法。

42. 发明授权

US07645774B2 Cannabinoid receptor ligands 失效
标题翻译：大麻素受体配体
公开(公告)号：US07645774B2
公开(公告)日：2010-01-12
申请号：US11197979
申请日：2005-08-05
申请人： Richard J. Friary , Joseph A. Kozlowski , Bandarpalle B. Shankar , Michael K. C. Wong , Guowei Zhou , Brian J. Lavey , Neng-Yang Shih , Ling Tong , Lei Chen , Youheng Shu
发明人： Richard J. Friary , Joseph A. Kozlowski , Bandarpalle B. Shankar , Michael K. C. Wong , Guowei Zhou , Brian J. Lavey , Neng-Yang Shih , Ling Tong , Lei Chen , Youheng Shu
IPC分类号： A61K31/445 , C07D211/26
CPC分类号： C07D401/12 , C07D211/26 , C07D211/96 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要： There are disclosed compounds of the formula I: or a pharmaceutically acceptable salt of the compound, which exhibit anti-inflammatory and immunomodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds.
摘要翻译：公开了具有抗炎和免疫调节活性的式I化合物或化合物的药学上可接受的盐。还公开了含有所述化合物的药物组合物。

43. 发明申请

US20090111803A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS 有权
标题翻译：用于治疗炎症性疾病的化合物
公开(公告)号：US20090111803A1
公开(公告)日：2009-04-30
申请号：US12338353
申请日：2008-12-18
申请人： Wensheng Yu , Ling Tong , Lei Chen , Joseph A. Kozlowski , Brian J. Lavey , Neng-Yang Shih , Vincent S. Madison , Guowei Zhou , Peter Orth , Zhuyan Guo , Michael K.C. Wong , De-Yi Yang , Seong Heon Kim , Bandarpalle B. Shankat
发明人： Wensheng Yu , Ling Tong , Lei Chen , Joseph A. Kozlowski , Brian J. Lavey , Neng-Yang Shih , Vincent S. Madison , Guowei Zhou , Peter Orth , Zhuyan Guo , Michael K.C. Wong , De-Yi Yang , Seong Heon Kim , Bandarpalle B. Shankat
IPC分类号： A61K31/5377 , C07D233/02 , A61K31/4178 , C07D403/02 , C07D277/20 , A61K31/426 , C07D401/14 , A61K31/4709 , A61P19/02 , A61P37/00 , A61P9/00 , A61P29/00 , A61K31/4545 , C07D215/00 , A61K31/4439 , C07D403/14 , A61K31/506 , A61K31/497 , C07D413/14
CPC分类号： C07D401/14 , C07D403/06 , C07D409/14 , C07D413/14 , C07D417/14
摘要： This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF—or combinations thereof.
摘要翻译：本发明涉及式（I）化合物或其药学上可接受的盐，溶剂合物或异构体，其可用于治疗由MMP，ADAM，TACE，TNF-或其组合介导的疾病或病症。

44. 发明申请

US20080119487A1 NOVEL NON-IMIDAZOLE COMPOUNDS 审中-公开
标题翻译：新型非咪唑化合物
公开(公告)号：US20080119487A1
公开(公告)日：2008-05-22
申请号：US11943315
申请日：2007-11-20
申请人： Robert G. Aslanian , Neng-Yang Shih , Pauline C. Ting , Michael Y. Berlin , Stuart B. Rosenblum , Kevin D. McCormick , Wing C. Tom , Christopher W. Boyce , Pietro Mangiaracina , Mwangi W. Mutahi , John J. Piwinski
发明人： Robert G. Aslanian , Neng-Yang Shih , Pauline C. Ting , Michael Y. Berlin , Stuart B. Rosenblum , Kevin D. McCormick , Wing C. Tom , Christopher W. Boyce , Pietro Mangiaracina , Mwangi W. Mutahi , John J. Piwinski
IPC分类号： A61K31/495 , A61K31/445 , A61K31/435 , A61P27/14 , A61P11/02
CPC分类号： C07D213/73 , A61K31/435 , A61K31/445 , A61K31/495 , C07D401/12 , C07D401/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D498/04
摘要： Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I.Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I.Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.
摘要翻译：公开的是式的新化合物还公开了包含式I化合物的药物组合物。还公开了治疗各种疾病或病症的方法，例如过敏，过敏诱发的气道反应和充血（例如，鼻拥塞）。还公开了使用组合式I化合物来治疗各种疾病或病症的方法，例如过敏，过敏诱发的气道反应和充血（例如，鼻塞）具有H 1受体拮抗剂。

45. 发明申请

US20080039439A1 Alpha2C adrenoreceptor agonists 失效
标题翻译： α2C肾上腺素受体激动剂
公开(公告)号：US20080039439A1
公开(公告)日：2008-02-14
申请号：US11705673
申请日：2007-02-13
申请人： Kevin McCormick , Christopher Boyce , Neng-Yang Shih , Chia-Yu Huang , Robert Aslanian , Salem Fevrier , Bo Liang , Rong-qiang Liu , Ruiyan Liu , Pietro Mangiaracina , Manuel de Lera Ruiz , Younong Yu , Lisa Guise-Zawacki , Junying Zheng
发明人： Kevin McCormick , Christopher Boyce , Neng-Yang Shih , Chia-Yu Huang , Robert Aslanian , Salem Fevrier , Bo Liang , Rong-qiang Liu , Ruiyan Liu , Pietro Mangiaracina , Manuel de Lera Ruiz , Younong Yu , Lisa Guise-Zawacki , Junying Zheng
IPC分类号： A61K31/535 , A61K31/502 , A61K31/54 , A61K31/553 , A61P1/00 , A61P25/00 , A61P37/00 , A61P9/00 , C07D241/36 , C07D279/06 , C07D498/04 , C12N5/06
CPC分类号： C07D413/14 , C07D241/36 , C07D279/06 , C07D403/06 , C07D413/06 , C07D417/06 , C07D417/14 , C07D471/04 , C07D498/04
摘要： In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.
摘要翻译：在其许多实施方案中，本发明涉及可用作α2C肾上腺素能受体激动剂的新型苯基吗啉和苯硫基吗啉化合物，含有该化合物的药物组合物，以及治疗，预防，抑制或改善一种或多种与 α2C肾上腺素能受体激动剂，使用这些化合物或药物组合物。

46. 发明申请

US20070244142A1 Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor 有权
标题翻译： 8 - [{1-（3,5-双 - （三氟甲基）苯基） - 乙氧基） - 甲基] -8-苯基-1,7-二氮杂 - 螺[4.5]癸-2-酮的盐酸盐和制备方法因此
公开(公告)号：US20070244142A1
公开(公告)日：2007-10-18
申请号：US11732548
申请日：2007-04-04
申请人： Mengwei Hu , Sunil Paliwal , Neng-Yang Shih , Frank Guenter , Ingrid Mergelsberg
发明人： Mengwei Hu , Sunil Paliwal , Neng-Yang Shih , Frank Guenter , Ingrid Mergelsberg
IPC分类号： A61K31/4747 , C07D471/10
CPC分类号： C07D471/10 , A61K31/435 , A61K31/495 , A61K45/06 , C07B2200/13
摘要： Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.
摘要翻译：公开了（5S，8S）-8 - [{（1R）-1-（3,5-双 - （三氟甲基）苯基） - 乙氧基} - 甲基] -8-苯基-1,1-二甲基吡啶的盐酸盐和甲苯磺酸盐结晶盐形式， 7-二氮杂螺[4.5]癸烷-2-酮，其制备方法。

47. 发明授权

US07220735B2 Benzimidazolone histamine H3 antagonists 失效
标题翻译：苯并咪唑酮组胺H3拮抗剂
公开(公告)号：US07220735B2
公开(公告)日：2007-05-22
申请号：US10414943
申请日：2003-04-16
申请人： Pauline C. Ting , Robert G. Aslanian , Michael Y. Berlin , Christopher W. Boyce , Jianhua Cao , Pietro Mangiaracina , Kevin D. McCormick , Mwangi W. Mutahi , Stuart B. Rosenblum , Neng-Yang Shih , Daniel M. Solomon , Wing C. Tom , Qingbei Zeng
发明人： Pauline C. Ting , Robert G. Aslanian , Michael Y. Berlin , Christopher W. Boyce , Jianhua Cao , Pietro Mangiaracina , Kevin D. McCormick , Mwangi W. Mutahi , Stuart B. Rosenblum , Neng-Yang Shih , Daniel M. Solomon , Wing C. Tom , Qingbei Zeng
IPC分类号： A61K31/495
CPC分类号： C07D471/04 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14
摘要： Disclosed are novel compounds of the formula wherein R1 is benzimidazolone derivative, M1 and M2 are optionally substituted carbon or nitrogen, R2 includes optionally substituted aryl or heteroaryl, and the remaining variables are as defined in the specification, and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an H1 receptor antagonist.
摘要翻译：公开了下式的新化合物其中R 1是苯并咪唑酮衍生物，M 1和M 2是任选取代的碳或氮，R SUP > 2 包括任选取代的芳基或杂芳基，其余变量如说明书中所定义，其余变量如说明书中所定义; 还公开了包含式I化合物的药物组合物和使用式I化合物治疗各种疾病或病症如过敏，过敏引起的气道反应和充血（例如，鼻塞）的方法，以及使用式I化合物与H 1受体拮抗剂组合治疗所述疾病或病症。

48. 发明授权

US07217732B2 Cannabinoid receptor agonists 失效
标题翻译：大麻素受体激动剂
公开(公告)号：US07217732B2
公开(公告)日：2007-05-15
申请号：US10464174
申请日：2003-06-17
申请人： Joseph A. Kozlowski , Bandarpalle B. Shankar , Neng-Yang Shih , Ling Tong
发明人： Joseph A. Kozlowski , Bandarpalle B. Shankar , Neng-Yang Shih , Ling Tong
IPC分类号： A61K31/404 , C07D209/04
CPC分类号： C07D213/643 , C07D209/12 , C07D209/14 , C07D209/30 , C07D213/71 , C07D307/64 , C07D307/79 , C07D333/34 , C07D401/12 , C07D407/12
摘要： A compound of the formula or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R4, R5, R6, L1, L2, M, n, p, X, Y and Z are as described in the specification; pharmaceutical compositions thereof, methods of making said pharmaceutical compositions; and methods of use thereof.
摘要翻译：下式的化合物或其药学上可接受的盐，其中：R 1，R 2，R 3，R 4， R SUP，R 5，R 6，L 1，L 2，M，n，p， X，Y和Z如说明书所述; 药物组合物，制备所述药物组合物的方法; 及其使用方法。

49. 发明申请

US20070082913A1 Substituted heterocyclic compounds with CXCR3 antagonist activity 有权
标题翻译：取代的具有CXCR3拮抗剂活性的杂环化合物
公开(公告)号：US20070082913A1
公开(公告)日：2007-04-12
申请号：US11545201
申请日：2006-10-10
申请人： Seong Kim , Bandarpalle Shankar , Joseph Kozlowski , Stuart Rosenblum , Neng-Yang Shih
发明人： Seong Kim , Bandarpalle Shankar , Joseph Kozlowski , Stuart Rosenblum , Neng-Yang Shih
IPC分类号： A61K31/497 , A61K31/496 , C07D403/14
CPC分类号： C07D401/14 , C07D401/08 , C07D413/14
摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
摘要翻译：本申请公开了所述化合物或所述前体药物的所述化合物或其药学上可接受的盐，溶剂合物或酯的化合物或对映异构体，立体异构体，旋转异构体，互变异构体或前药，所述化合物具有式1所示的一般结构：或其药学上可接受的盐，溶剂合物或酯，其中各种部分在本文中定义。还公开了治疗趋化因子介导的疾病的方法，例如姑息治疗，疗效治疗，某些疾病和疾病如炎性疾病的预防性治疗（非限制性实例，牛皮癣），自身免疫性疾病（非限制性的例如，类风湿性关节炎，多发性硬化症），移植排斥反应（非限制性实例包括，同种异体移植排斥反应，异种移植物排斥），感染性疾病（例如结核性麻风病），固定药物爆发，皮肤迟发型超敏反应应答，I型糖尿病，病毒性脑膜炎和使用式1的化合物的肿瘤。

50. 发明申请

US20060281778A1 Compounds for inhibiting KSP Kinesin activity 审中-公开
标题翻译：用于抑制KSP驱动蛋白活性的化合物
公开(公告)号：US20060281778A1
公开(公告)日：2006-12-14
申请号：US11369625
申请日：2006-03-07
申请人： Jayaram Tagat , Timothy Guzi , Marc Labroli , Cory Poker , Angela Kerekes , Tao Yu , Hon-Chung Tsui , Neng-Yang Shih , Yushi Xiao , Sunil Paliwal
发明人： Jayaram Tagat , Timothy Guzi , Marc Labroli , Cory Poker , Angela Kerekes , Tao Yu , Hon-Chung Tsui , Neng-Yang Shih , Yushi Xiao , Sunil Paliwal
IPC分类号： A61K31/4745 , C07D498/02
CPC分类号： C07D495/04
摘要： The present invention provides compounds of Formula I (wherein R1, R3, X, W, Z and ring Y are as defined herein). The present invention also provides compositions comprising these compounds that are useful for treating cellular proliferative diseases or disorders associated with KSP kinesin activity and for inhibiting KSP kinesin activity.
摘要翻译：本发明提供式I化合物（其中R 1，R 3，X，W，Z和环Y如本文所定义）。本发明还提供了包含这些化合物的组合物，其可用于治疗与KSP驱动蛋白活性相关的细胞增殖性疾病或病症并抑制KSP驱动蛋白活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式